High-fat but not sucrose intake is essential for induction of dyslipidemia and non-alcoholic steatohepatitis in guinea pigs by Ipsen, David Højland et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 18, 2017
High-fat but not sucrose intake is essential for induction of dyslipidemia and non-
alcoholic steatohepatitis in guinea pigs
Ipsen, David Højland; Tveden-Nyborg, Pernille; Rolin, Bidda; Rakipovski, Günaj; Beck, Maria; Mortensen,
Line Winther; Færk, Lasse; Heegaard, Peter Mikael Helweg; Møller, Peter ; Lykkesfeldt, Jens
Published in:
Annals of Nutrition and Metabolism
Link to article, DOI:
10.1186/s12986-016-0110-1
Publication date:
2016
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Ipsen, D. H., Tveden-Nyborg, P., Rolin, B., Rakipovski, G., Beck, M., Mortensen, L. W., ... Lykkesfeldt, J. (2016).
High-fat but not sucrose intake is essential for induction of dyslipidemia and non-alcoholic steatohepatitis in
guinea pigs. Annals of Nutrition and Metabolism, 13, [51]. DOI: 10.1186/s12986-016-0110-1
RESEARCH Open Access
High-fat but not sucrose intake is essential
for induction of dyslipidemia and non-
alcoholic steatohepatitis in guinea pigs
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Line Winther Mortensen1, Lasse Færk1, Peter Mikael Helweg Heegaard3, Peter Møller4 and Jens Lykkesfeldt1*
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) and dyslipidemia are closely related. Diet plays an important
role in the progression of these diseases, but the role of specific dietary components is not completely understood.
Therefore, we investigated the role of dietary sucrose and fat/cholesterol on the development of dyslipidemia and
NAFLD.
Methods: Seventy female guinea pigs were block-randomized (based on weight) into five groups and fed a normal
chow diet (control: 4 % fat), a very high-sucrose diet (vHS: 4 % fat, 25 % sucrose), a high-fat diet (HF: 20 % fat, 0.
35 % cholesterol), a high-fat/high-sucrose diet (HFHS: 20 % fat, 15 % sucrose, 0.35 % cholesterol) or a high-fat/very
high-sucrose diet (HFvHS: 20 % fat, 25 % sucrose, 0.35 % cholesterol) for 16 and 25 weeks.
Results: All three high-fat diets induced dyslipidemia with increased concentrations of plasma cholesterol
(p < 0.0001), LDL-C (p < 0.0001) and VLDL-C (p < 0.05) compared to control and vHS. Contrary to this, plasma
triglycerides were increased in control and vHS compared to high-fat fed animals (p < 0.01), while circulating
levels of free fatty acids were even between groups. Histological evaluation of liver sections revealed non-
alcoholic steatohepatitis (NASH) with progressive inflammation and bridging fibrosis in high-fat fed animals.
Accordingly, hepatic triglycerides (p < 0.05) and cholesterol (p < 0.0001) was increased alongside elevated levels
of alanine and aspartate aminotransferase (p < 0.01) compared to control and vHS.
Conclusion: Collectively, our results suggest that intake of fat and cholesterol, but not sucrose, are the main
factors driving the development and progression of dyslipidemia and NAFLD/NASH.
Keywords: Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis, Dyslipidemia, High-fat diet, Sucrose,
Guinea pigs, Cholesterol
Background
Non-alcoholic fatty liver disease (NAFLD) is the most
common chronic liver disease in the Western world [1]
and is closely associated with dyslipidemia [2, 3]. Affect-
ing more than 30 % of the general adult population and
with the potential to progress from simple steatosis to
irreversible and life-threatening non-alcoholic steato-
hepatitis (NASH), it is an important public health
concern [1, 4]. Disease progression is instigated by a
series of parallel hits such as inflammation and oxida-
tive stress, causing hepatocyte damage (e.g. metabolic
dysfunction, DNA injury and apoptosis) and irrevers-
ible fibrosis, ultimately leading to cirrhosis and liver
failure [5]. Although the etiology of NAFLD is not
yet fully elucidated, changes in food composition are
believed to play an essential role in disease progres-
sion [4]. Diets rich in saturated fat, cholesterol and
non-complex carbohydrates (e.g. the disaccharide: su-
crose) have been shown to induce dyslipidemia and
hepatic lipid accumulation and are suggested to play
a key role in the development of NASH in human
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patients [6–9]. However, potential interactions of different
dietary components and whether certain components are
more likely to cause NAFLD has not been determined
[10]. Fat and cholesterol promotes oxidative stress, hepa-
tocellular apoptosis, steatosis and NASH [5]. Furthermore,
previous results from our group have indicated that
sucrose may affect the development of NAFLD in guinea
pigs [11]. Guinea pigs are one of the few species carrying
the majority of their cholesterol in low density lipoprotein
(LDL) particles; hence exhibiting a lipoprotein profile
similar to that of humans [12–14]. Furthermore, we and
others have reported that guinea pigs subjected to long-
term feeding with diets high in fat, cholesterol and sucrose
develop hepatic steatosis in accordance with NAFLD
[11, 15, 16].
In the present study, we investigated the specific
effects of dietary sucrose and fat/cholesterol, alone and
in combination, on the development of dyslipidemia and
NAFLD or NASH.
Methods
Animals and experimental design
Seventy female Hartley guinea pigs, 10 weeks old
(Charles River Laboratories, Lyon, France), were block-
randomized (based on body weight (BW)) into five hom-
ologous groups (n = 14) following one week of acclima-
tion. The animals were group-housed in floor pens with
wood shavings, hay, straw and environmental enrich-
ment. Food and water was provided ad libitum and a
12 h light–dark cycle with temperatures between 20–
24 °C was maintained. Groups were fed either chow
(control), or chow-based diets of very high-sugar (vHS),
high-fat (HF), high-fat/high-sugar (HFHS) or high-fat/
very high-sugar (HFvHS) diets (Ssniff Spezialdiäten
GmbH, Soest, Germany) (Table 1). The diets were stored
at −20 °C and freshly thawed twice weekly (complete
dietary compositions are shown Additional file 1).
Food intake in each group was estimated daily by weigh-
ing feed-remains prior to refill. After either 16 or 25 weeks,
guinea pigs were semi-fasted over-night (no feed, but ac-
cess to hay), pre-anaeshetized with 0.08 ml/kg BW
Zoletil-mix, placed on isoflurane and euthanized by de-
capitation following an intra-cardial blood sample as
previously described [11, 17]. Organs were rapidly col-
lected, rinsed in phosphate buffered saline, weighed and
stored at −80 °C or in paraformaldehyde for histological
examinations.
Oral glucose tolerance test
An oral glucose tolerance test (OGTT) was performed
after 15 and 24 weeks. Guinea pigs were semi-fasted
overnight and dosed orally with a 50 % glucose solution
(Amgros I/S, Copenhagen, Denmark) by syringe (2 g
glucose/kg BW). Blood glucose was measured with an
Accu-Chek Aviva glucometer (Roche A/S Diagnostics,
Basel, Switzerland) in triplicate or duplicates at time
points 0, 15, 30, 45, 90, 120 and 180 min post-glucose
consumption.
Plasma samples
All samples obtained at euthanasia were collected intra-
cardially, whereas samples taken during the study period
(baseline triglyceride (TG) and total cholesterol (TC))
were collected from the vena saphena [18]. Samples for
alkaline phosphatase (ALP) and free fatty acids (FFA)
were collected in heparin and NaF-coated microvettes
(Sarstedt, Nümbrecht, Germany), respectively. Alanine
aminotransferase (ALT), aspartate aminotransferase (AST),
TG and TC were collected in K3EDTA-coated microvettes
(Sarstedt, Nümbrecht, Germany). Blood samples for all
other analyses were collected in a K3EDTA-flushed 10 ml
syringe. The analyses of ALP, AST, ALT, FFA, TG and
baseline TC were performed on a Cobas 6000 (Roche
Diagnostic Systems, Berne, Switzerland) according to
manufacturer’s specifications. Lipoprotein fractions (very
low density lipoprotein (VLDL), LDL and high density
lipoprotein (HDL)) alongside TC at week 16 and 25 were
analyzed by the Lipoprotein Analysis Laboratory (Wake
Forest School of Medicine, Winston-Salem, North
Carolina, USA) as described previously [19]. Serum amyl-
oid A was determined by ELISA (Tridelta Development
Ltd, Phase SAA Assay, Kildare, Ireland) and expressed
as μg/ml porcine SAA equivalents as previously de-
scribed [20].
Liver samples
TC and TG were analyzed on liver homogenates sam-
pled from the left lateral (lobus hepatis sinister lateralis)
and right medial (lobus hepatis dexter medialis) lobes on
a Cobas 6000 according to manufacturer’s specifications
and as previously described [11].
Telomere length
The average telomere length was measured from total
genomic DNA from liver tissue using real-time quantita-
tive PCR as described previously [21, 22]. For measure-
ment of telomere repeat copies (T), the primers were:
Table 1 Composition of diets
Nutrient (g/kg diet) Control vHS HF HFHS HFvHS
Protein 168 168 168 167 168
Fat 42 43 200 200 199
Carbohydrates (total) 471 535 363 379 411
Cholesterol – – 3.5 3.5 3.5
Sucrose (total amount added
to the diet)
– 250 – 150 250
Metabolizable energy (MJ/kg) 12.3 13.4 16.4 16.7 17.2
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telg- 5′-CGG TTT GTT TGG GTT TGG GTT TGG
GTT TGG GTT TGG GTT-3′ and telc- 5′-GGC TTG
CCT TAC CCT TAC CCT TAC CCT TAC CCT TAC
CCT-3′. Cycling conditions were: 2 min at 50 °C, 2 min
of 95 °C, followed by 2 cycles of 95 °C for 15 s, 52 °C for
15 s and 36 cycles of 95 °C for 15 s, 62 °C for 15 s and
71 °C for 15 s. For measurement of single copy gene (S),
the primers were: globin- 5′- ACT GGT CTA GGA
CCC GAG AAG-3′ and globin- 5′- TCA ATG GTG
CCT CTG GAG ATT-3′. The PCR was carried out in a
384-well 7900HT FAST Real-Time PCR System (Applied
Biosystems, Slangerup, Denmark) using a reaction mix
with 10–20 ng of genomic DNA in 1× SYBR® Green
PCR Master Mix (Applied Biosystems, Slangerup,
Denmark). The results are reported as the relative telo-
mere length, i.e. the ratio of telomere repeat copy number
(T) to single copy gene (S) copy number (T/S ratio).
Single cell gel electrophoresis (comet) assay
DNA strand breaks were measured as previously
described [23]. Strand breaks were visually scored and
assigned to one of five classes in a blinded fashion as
described by [23]. Cells treated with Ro19-8022 (gift
from F. Hoffmann-La Roche, Basel, Switzerland) and
white light were used as controls. The level of DNA
damage was expressed as a total score calculated as:

Number of class I ⋅ 1þ Number of class II ⋅ 2
þ Number of class III ⋅ 3þ Number of class IV ⋅ 4
þ Number of class V ⋅ 5

−total number of scored comets
Histology
Paraformaldehyde fixed sections of the left lateral liver
lobe were imbedded in paraffin cut into 2–4 μm cross-
sections and stained with Mayer’s Haematoxylin and
Eosin (H&E) or Masson’s trichrome stain as previously
described [11]. All histological evaluations were per-
formed in a blinded fashion. Sections were evaluated by
scoring three lobuli, defined by the presence of at least
two portal areas surrounding a central vein, and in
accordance with the semi-quantitative scoring scheme
suggested by Kleiner et al. [24] as follows: Steatosis was
graded from 0–3 reflecting the amount of lipids: 0: <5 %;
1: 5–33 %; 2: >33–66 %; and 3: >66 %. Lobular inflam-
mation was evaluated as the number of inflammatory
foci (defined as at least three inflammatory cells in close
proximity of each other) in a ×200 field as 0: no foci; 1:
<2 foci per field; 2: 2–4 foci per field; 3: >4 foci or dif-
fuse infiltration of the entire field. Portal inflammation
was scored as 0: none to minimal, 1: greater than min-
imal. The presence of ballooning hepatocytes were ac-
knowledged as 0: none; 1: few (but definite ballooning
hepatocytes); or 2: many ballooning hepatocytes. Fibrosis
was evaluated on entire sections stained by Masson’s
trichrome. Fibrosis was graded as: 0: not present; 1: peri-
sinusoidal or periportal; 1A: mild, zone 3 perisinusoidal;
1B: moderate, zone 3 perisinusoidal; 1C: portal/peripor-
tal; 2: perisinusoidal and portal/periportal; 3: bridging
fibrosis; 4: cirrhosis.
Statistical analysis
All statistical analyses were performed in SAS Enterprice
Guide 7.1 (SAS Institute Inc, Cary, North Carolina,
USA) and graphs were made in GraphPad Prism 6.06
(GraphPad Software, La Jolla, California, USA). Weight,
plasma TG and TC were analyzed by a generalized
linear mixed model with random effect of animals.
The rest of the data was analyzed using a generalized
linear model and presented as means with standard
deviations (SD). Data with inhomogeneous variance
was logarithmically transformed and then analyzed.
Subsequently, data was back-transformed and pre-
sented as geometric means with 95 % confidence in-
tervals. Tukey’s multiple comparisons test was used in
all cases. Ordinal data (histopathological liver scores),
DNA damage scores and telomere lengths were
analyzed using non-parametric statistics followed by
Bonferroni post-hoc test and are presented as me-
dians with range. A p-value below 0.05 was consid-
ered statistically significant.
Results
Dietary regimes and OGTT
There were no differences in BW between groups at
study start. Control and vHS gained more weight result-
ing in significantly higher BW compared to the high-fat
diet (HFD) groups (HF, HFHS and HFvHS) after
16 weeks (p < 0.01) (Fig. 1a). After 25 weeks, BW only
differed between control and HF (p < 0.05) and vHS and
HFD (p < 0.001). Initially, average energy intake increased
in all groups, after which they declined and then remained
stable throughout the study period (Fig. 1b). Cumulative
weekly energy intake was higher in vHS compared to
HFvHS (p < 0.01), but similar among other groups, after
16 weeks (Fig. 1c). After 25 weeks, cumulative energy
intake was higher in vHS (p < 0.0001), HFHS (p < 0.001)
and HFvHS (p < 0.01) compared to control and increased
in vHS compared to HF (p < 0.01) and HFvHS (p < 0.05)
(Fig. 1d). No difference between dietary regimes and
glucose tolerance was recorded at either time-point
(Additional file 2).
Dyslipidemia and inflammation
Plasma TC and TG (Fig. 2a and b) did not differ between
groups at baseline. At 16 and 25 weeks, plasma TC was
increased in HF, HFHS and HFvHS compared to control
Ipsen et al. Nutrition & Metabolism  (2016) 13:51 Page 3 of 10
Fig. 1 Weight and energy intake during the study period. a Control and vHS animals weighed more than high-fat fed animals after 16 weeks.
vHS continued to weigh more compared to high-fat fed animals after 25 weeks, while control only weighed more than HF. Average weekly
energy intake (b) and weekly cumulative energy intake per group until week 16 (c) and 25 (d) suggest that vHS had greater energy intake
compared to the other groups. Means with SD, n = 7–14. HFD vs. Control: **** p < 0.0001 *** p < 0.001 ** p < 0.01. HFD vs. vHS: ### p < 0.001
## p < 0.01 # p < 0.05. HF vs. Control: ¤ p < 0.05
Fig. 2 Plasma total cholesterol and triglycerides. After 16 and 25 weeks, total cholesterol (a) was significantly increased by high-fat diets, while
triglycerides (b) increased in control and vHS. Geometric means with 95 % confidence interval, n = 7–14. HFD vs. Control: **** p < 0.0001
** p < 0.01. HFD vs. vHS: #### p < 0.0001
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and vHS (p < 0.0001). Contrary to this, plasma TG was
elevated after 16 weeks (p < 0.0001) and 25 weeks (p <
0.01) in control and vHS compared to HFD. FFA did not
differ between any groups at any time point. After
16 weeks on the diets, VLDL-C (p < 0.05) and LDL-C
(p < 0.0001) concentrations were increased in HFD
groups compared to control and vHS (Table 2). The
dyslipidemia persisted after 25 weeks, i.e. increased
VLDL-C (p < 0.001) and LDL-C (p < 0.0001) in HFD
groups compared to control and vHS (Table 3). While
HDL-C increased upon high-fat feeding, this was not
statistically significant relative to control and vHS
after 16 or 25 weeks. SAA concentrations were lower
in HF (p < 0.01) and HFvHS (p < 0.001) compared to
control and lower in all HFD groups compared to
vHS (p < 0.01) after 16 weeks (Table 2). At 25 weeks,
only HFvHS displayed lower SAA compared to vHS
(p < 0.01) (Table 3).
Liver biochemistry and genomic damage
Compared to control and vHS, liver weight relative to
BW increased upon high-fat feeding after 16 and 25 weeks
(p < 0.0001) (Table 2 and 3). Similar results were observed
for absolute liver weights (Additional file 3), substantiating
that increased relative liver weights were not caused by
lower BW in HFD groups. Accordingly, lipids were in-
creased in the liver of the high-fat fed animals: Hepatic
TC was increased in the HF, HFHS and HFvHS compared
to both control and vHS (p < 0.0001) on both time-points
(Fig. 3a). After 16 weeks hepatic TG was increased in the
HFD groups compared to vHS (p < 0.05). After 25 weeks,
an increase in hepatic TG was seen compared to control
(p < 0.05), but not when compared to vHS animals
(Fig. 3b). Compared to controls and vHS, plasma ALT
(p < 0.001) and AST (p < 0.0001) were increased in all
HFD groups at 16 weeks (Table 2) and remained ele-
vated after 25 weeks (ALT p < 0.01, AST p < 0.0001)
(Table 3). Plasma ALP did not differ between any
groups at any time point (p > 0.05). Genomic damage
as assessed by the length of telomeres and level of DNA
strand breaks did not differ between groups (p > 0.05)
(Additional file 4).
Histology
Hepatic steatosis (grade 3), evident as micro- and
macrovesicular lipid accumulation in zone 3, was found
in most HFD animals, but not in control and vHS ani-
mals after 16 and 25 weeks (p < 0.01) (Fig. 3c, g and h).
At week 16, lobular inflammation was not significantly
higher in HFD groups compared to vHS. However, hep-
atic inflammation continued to progress in all HFD
groups, resulting in severe inflammation (grade 3),
which was significantly higher compared to control and
vHS at week 25 (p < 0.05) (Fig. 3d). Concurrently, hep-
atocyte ballooning was more prominent in HFD groups
at both time-points compared to control and vHS (p <
0.05) (Fig. 3e). Fibrosis (grade 1–3) was significantly in-
creased in all HFD groups compared to control and vHS
at week 16 (p < 0.05). At week 25, fibrosis, bridging be-
tween central veins (grade 3), was seen in almost all
HFD animals, while fibrosis was absent in control and
vHS (p < 0.01) (Fig. 3f, i and j). Portal inflammation was
absent in all groups at both time points, apart from a
single control animal at 16 weeks. The exact histological
scoring is provided in Additional file 5.
Discussion
The present study shows that dietary fat and cholesterol,
but not sucrose, are the main factors driving the progres-
sion of dyslipidemia and NAFLD to NASH in a guinea pig
model. Additionally, adding sucrose to a high-fat diet does
not exacerbate the metabolic or hepatic consequences of a
high-fat diet per se.
Expectedly, addition of cholesterol to the dietary
regime increased circulating levels of TC, similar to find-
ings of other studies utilizing cholesterol-rich [25, 26] or
high-fat diet [27]. Though Plasma TC and TG concentra-
tions were not affected by addition of sucrose consistent
Table 2 Circulating lipids, relative liver weight and biochemical markers after 16 weeks on diets
Control vHS HF HFHS HFvHS
VLDL-C (mM) a 0.19 (0.11–0.33) 0.18 (0.11–0.30) 1.01 (0.60–1.72) ** ### 0.89 (0.52–1.51) ** ## 0.68 (0.40–1.16) * #
LDL-C (mM) a 1.22 (0.92–1.62) 1.55 (1.17–2.06) 9.04 (6.81–12.0) **** #### 7.86 (5.90–10.4) **** #### 6.54 (4.93–8.68) **** ####
HDL-C (mM) a 0.04 (0.03–0.06) 0.04 (0.03–0.06) 0.07 (0.04–0.10) 0.10 (0.06–0.15) 0.09 (0.06–0.15)
FFA (mM) 0.77 ± 0.23 0.68 ± 0.16 0.50 ± 0.15 0.51 ± 0.09 0.52 ± 0.21
SAA (μg/mL) a 89.4 (47.5–168) 182 (91.8–359) 14.3 (7.22–28.3) ** #### 22.5 (10.7–47.5) ## 10.8 (5.77–20.4) *** ####
% Liver weight a 2.16 (1.92–2.43) 2.29 (2.03–2.57) 4.72 (4.19–5.31) **** #### 4.63 (4.11–5.21) **** #### 4.30 (3.82–4.84) **** ####
ALT (U/L) a 43.1 (34.1–54.7) 32.4 (25.6–41.1) 92.5 (73.0–117) *** #### 106 (83.8–128) ****#### 98.1 (76.0–127)*** ####
AST (U/L) a 67.0 (47.3–95.2) 51.5 (36.3–73.1) 403 (284–572) **** #### 450 (317–639) **** #### 323 (221–471) **** ####
ALP (U/L) 70.3 ± 5.53 60.7 ± 18.5 59.0 ± 14.6 53.9 ± 9.19 51.9 ± 17.3
n = 7. Mean with SD. Compared to control **** p < 0.0001*** p < 0.001 ** p < 0.01 * p < 0.05. Compared to vHS #### p < 0.0001### p < 0.001 ## p < 0.01 # p < 0.05
a Data analysis performed on log10 transformed data, presented as geometric means with 95 % confidence interval
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with results from mice and rats fed sucrose at levels of
32–35 % of total caloric intake [28, 29], circulating levels
of TC and TG upon sucrose feeding have also been re-
ported [30–33] It is possible that sucrose induced dyslip-
idemia differs mechanistically from the high fat induced
[31], and moreover very high levels (≥60 %) of sucrose are
applied to induce dyslipidemia [31–33]. Thus, it is possible
that higher dietary sucrose concentrations may have been
necessary to promote dyslipidemia in the current study;
indeed calories originating from sucrose and fat were not
equal potentially confounding the effect of sucrose. How-
ever, the translational relevance of models utilizing ex-
tremely high levels of sucrose have been questioned [34].
Consequently, the levels of dietary sucrose in this study
may have more relevance to human consumption, albeit
still being high.
Decreased levels of hepatic LDL-receptors and con-
comitant increased levels of circulating TC and LDL-C
has been reported in guinea pigs subjected to a high-fat
diet [35]. Accordingly, we found that LDL-C and VLDL-
C increased upon high-fat feeding, regardless of dietary
content of sucrose. This contradicts previous findings of
a sucrose imposed elevation of TC and LDL-C when
added to a high-fat diet in male guinea pigs [13, 36]. The
observed dissimilarity may be due to differences in
dietary composition as the latter high-fat diets did not
contain excess cholesterol [13, 36] and/or a gender associ-
ated effect, as female rats—in contrast to males—proved
resistant to sucrose-induced hypertriglyceridemia [37]. In
agreement with our findings, circulating levels of lipids
did not increase in humans placed on eucaloric diets, con-
suming 20 % of calories as sucrose for 10 weeks [38].
BW increased in all groups over time, but high-fat fed
animals do not become obese and compared to the con-
trol and vHS groups, this is in accordance with previous
results by us and others [11, 13, 16, 35]. Lack of compar-
able weight gain despite similar caloric intake might
partly be due to hepatic lipid accumulation, rendering
lipids unavailable for other tissues. After 16 weeks, HFHS
and HFvHS increased energy-intake compared to control
and consequently weight differences were eliminated be-
tween HFHS, HFvHS and control. Compared to control,
HF also tended to increase energy-intake, but not enough
to completely eliminate the weight difference. The appar-
ent increase in BW observed for vHS after week 16 was
due to the randomization procedure: animals were
randomized, but not block-randomized based on weight
at euthanasia and by chance, most of the animals with the
highest BW were randomly chosen to continue on the
diet. Regardless, vHS did not develop dyslipidemia or
NAFLD. Thus, weight differences are not thought to influ-
ence the results of this study, and animals exposed to
either vHS or high-fat diet were not obese compared to
controls.
FFA release increases with increasing fat mass in
humans [39] and the lack of increased FFA concentrations
is likely to reflect the absence of obesity as reported in a
non-obese rabbit-model of NASH [40]. Furthermore,
plasma TG was not increased in response to the high-fat
diet. This could be due to increased TG clearance from
the blood and/or decreased hepatic TG production.
Accordingly, guinea pigs on high-fat diet (25.1 % fat) dis-
played reduced plasma TG compared to their low-fat fed
counterparts [13]. Lipoprotein lipase activity was in-
creased by high-fat feeding, most likely contributing to the
decreased circulating levels of TG [13]. Similarly, plasma
TG was also lower in rats fed a high-fat, high-cholesterol
diet compared to chow or a high-fat diet without choles-
terol [41]. In these rats, hepatic microsomal triglyceride
transfer protein mRNA expression was suppressed, poten-
tially limiting hepatic VLDL-TG production [41]. Indeed,
hepatic TG production may be compromised as NAFLD
progresses from simple steatosis towards steatohepatitis.
In humans, NASH is associated with impaired VLDL
synthesis and secretion and reduced apoB100 synthesis
[42, 43]. Hence, hepatic retention of TG, limiting TG
availability for storage in adipose tissue, may constitute a
causal mechanism in the progression of NASH in the
Table 3 Circulating lipids, relative liver weight and biochemical markers after 25 weeks on diets
Control vHS HF HFHS HFvHS
VLDL-C (mM) a 0.12 (0.07–0.20) 0.13 (0.08–0.23) 1.02 (0.60–1.74) **** #### 1.38 (0.81–2.35) **** #### 0.89 (0.52–1.51) **** ###
LDL-C (mM) a 0.99 (0.74–1.31) 1.15 (0.87–1.52) 7.74 (5.83–10.3) **** #### 7.83 (5.90–10.4) **** #### 7.38 (5.56–9.79) **** ####
HDL-C (mM) a 0.03 (0.02–0.05) 0.04 (0.02–0.06) 0.06 (0.04–0.10) 0.08 (0.05–0.12) 0.07 (0.04–0.10)
FFA (mM) 0.48 ± 0.22 0.61 ± 0.12 0.58 ± 0.13 0.64 ± 0.13 0.43 ± 0.17
SAA (μg/mL) a 46.6 (24.8–87.7) 88.3 (46.9–166) 20.9 (10.6–41.3) 48.1 (24.3–95.2) 12.3 (6.56–23.2) ##
% Liver weight a 2.07 (1.84–2.32) 2.55 (2.27–2.87) 4.90 (4.35–5.51) **** #### 5.19 (4.61–5.84) **** #### 4.97 (4.42–5.59)**** ####
ALT (U/L) a 37.0 (29.2–46.9) 30.2 (23.8–38.2) 77.7 (61.3–98.3) ** #### 101 (79.7–128) **** #### 86.4 (68.3–109) *** ####
AST (U/L) a 43.6 (30.7–61.8) 43.7 (30.8–62.0) 259 (183–368) **** #### 428 (302–607) **** #### 445 (314–631) **** ####
ALP (U/L) 60.1 ± 4.88 59.6 ± 13.1 45.9 ± 5.18 43.3 ± 1.70 47.0 ± 7.05
n = 7. Mean with SD. Compared to control **** p < 0.0001*** p < 0.001 ** p < 0.01. Compared to vHS #### p < 0.0001 ### p < 0.001
a Data analysis performed on log10 transformed data, presented as geometric means with 95 % confidence interval
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non-obese phenotype of the dyslipidemic guinea pig
model.
Guinea pig SAA - a systemic marker of inflammation
[20] - was not induced by high-fat feeding at any of the
two time points, similar to results from high fat fed
(15 % fat, 1.35 % cholesterol) mice [44]. Our findings
may suggest that systemic inflammation is not promin-
ent in this model, at least when assessed by systemic
SAA level. Alternatively, it could be speculated that low
SSA levels was due to reduced liver function, supported
by histopathology and increased ALT and AST levels,
rendering the liver unable to produce and/or secrete
SAA.
Our study revealed hepatocyte ballooning after
16 weeks of high-fat feeding, signifying the presence of
NASH and distinguishing it from simple steatosis [45, 46].
This is further supported by the recorded inflammatory
foci and progression of fibrosis in the HFD groups. While
hepatic fibrosis is not necessary for the diagnosis of
NASH, it represents a critical step in the progression of
the disease, setting the stage for further liver damage such
as cirrhosis and hepatocellular carcinoma [41]. However,
high-fat diet models often induce mild hepatic fibrosis
while rarely leading to severe progressive fibrosis [47, 48],
except in guinea pigs [11]. After 16 weeks, guinea pigs in
the HF and HFvHS group exhibited mild fibrosis, while
the HFHS group already displayed bridging fibrosis (grade
3). After 25 weeks, all three HFD groups had formed
bridging fibrosis. Consistent with our findings of circulat-
ing levels of lipids, sucrose feeding alone did not induce
NAFLD, nor did it affect hepatic outcomes when added to
a high-fat diet. Contrary to our results, 60–70 % sucrose
promoted development of hepatic steatosis in both rats
[49–51] and mice [52, 53]. However, while levels of hep-
atic inflammatory cytokines were increased [49], hepatic
triglycerides were not significantly elevated [49, 51]. Thus,
sucrose is seemingly not able to induce NASH.
Diseases characterized by chronic tissue regeneration,
such as cirrhosis ensuing from progressive NASH, ultim-
ately results in telomere shortening [54]. This promotes
genomic instability paralleled by DNA strand damage
which may constitute an underlying disease aspect playing
an important role in NAFLD, especially with regards to
fibrosis progression [54]. However, DNA strand breaks
and telomere length was not different between groups.
Consequently, these do not seem to be underlying mecha-
nisms of NAFLD and NASH in this particular animal
model. The null results on hepatic DNA damage is in
keeping with earlier results in rats showing no altered
levels of DNA strand breaks after feeding with saturated
fats [55] and sucrose [56–59]. Alternatively, livers may
have to become cirrhotic before notable telomere shorten-
ing can be detected, which may also explain the absence
of telomere shortenings.
Conclusion
Dietary sucrose alone or in combination with a high-fat
diet did not affect the development of dyslipidemia or
NASH. Thus, disease development appears to be driven
mainly by dietary fat and cholesterol, but the current
study is not able to distinguish between effects of dietary
fat and cholesterol. Furthermore, the present diets con-
tained high levels of saturated fatty acids and extrapola-
tion of the results to dietary regimes differing in fatty
acid composition and content should be done with cau-
tion. However, encompassing a similar histopathology
indicates that the model may closely resemble the human
condition. Based on the systemic and hepatic changes
observed, our findings may reiterate the idea of fat and
cholesterol as critical dietary factors with regards to dis-
ease progression.
Additional files
Additional file 1: Exact dietary composition. The complete dietary
composition including fatty acid composition. *Vitamin & trace element
content (addition per kg feed): 25.0 IU Vitamin A (E672), 1.50 IU, Vitamin
D3 (E671), 0.125 g Vitamin E (all-rac-alpha-tocopherylacetate) (3a700),
0.08 g Vitamin K3 (MNB), 0.08 g Vitamin B1 (Thiamine mononitrate),
0.03 g Vitamin B2 (Riboflavin), 0.05 g Ca Pantothenate, 0.025 g Vitamin
B6 (pyridoxol hydrochloride) (3a831), 0.00015 g Vitamin B12
(Cyanocobalamine), 0.09 g Niacin, 0.009 g Folic acid, 0.0005 g Biotin,
0.100 g Inositol, 0.100 g Iron (II)-sulfate monohydrate (E1), 0.005 Copper
(II)-sulfate pentahydrate (E4), 0.03 g Manganese (II)-sulfate monohydrate
(E5), 0.002 g Cobalt (II)-carbonate monohydrate (E3), 0.05 g Zinc sulfate
monohydrate (E6), 0.002 g Calcium iodate anhydrate (E2), 0.0001 g
Sodium selenite (E8). ** 1.00 g NaCl added to HFvHS as soybean isolate
contains approximately 1.5 % NaCl). (DOCX 17 kb)
Additional file 2: Oral glucose tolerance tests. High-fat diets did not
induce glucose intolerance as shown by oral glucose tolerance tests
conducted after 15 (A) and 24 weeks (B). Means with SD, n = 7. HFD vs.
(See figure on previous page.)
Fig. 3 Biochemical and histological characteristics of livers. Hepatic lipid content (a and b), histological scoring of liver sections in accordance to
[24] (c-f) and representative liver sections for control/vHS (g and i) and HFD (h and j). The arrow head and arrow indicates inflammatory cells and
fibrosis, respectively. Hepatic cholesterol was increased by high-fat feeding at 16 and 25 weeks (a), while hepatic triglycerides were significantly
increased in HFD groups after 25 weeks compared to control (b). Compared to control and vHS, HFD groups had grade 3 hepatic steatosis after
16 weeks, which persisted until the end of the study at 25 weeks (c, g and h). Similarly, high-fat diet induced progressive inflammation (d), hepatocyte
ballooning (e) and fibrosis (f, i and j). Geometric means with 95 % confidence interval (a), means with SD (b) and medians with range (c-f). Scale bar
50 μm (f and g) and 100 μm (h and i), n = 6–7 (HFvHS n = 6 for histology at week 16 due to technical difficulties). HFD vs. Control: **** p < 0.0001
** p < 0.01 * p < 0.05. HFD vs. vHS: #### p < 0.0001 ## p < 0.01 # p < 0.05
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Control: **** p < 0.0001 ** p < 0.01 * p < 0.05. HFD vs. vHS: #### p < 0.0001
### p < 0.001 # p < 0.05. Control vs. vHS: θθθθ p < 0.0001 θθθ p < 0.001
θ p < 0.05. (TIF 497 kb)
Additional file 3: Absolute liver weight. The absolute liver weights were
increased in HFD compared to Control and vHS after 16 and 25 weeks.
Means with SD, n = 7. HFD vs. Control: **** p < 0.0001. HFD vs. vHS:
### p < 0.001. HFD vs. vHS: ## p < 0.01. (TIF 211 kb)
Additional file 4: Hepatic telomere length and DNA strand breaks. T/S
expresses the ratio of the mean telomere repeat copies (T) to a reference
single copy gene (S) and did not differ between groups (A). Additionally,
the extent of DNA damage, measured as strand breaks, did not differ
between groups (B). Medians with range, n = 5–7. (TIF 442 kb)
Additional file 5: Frequencies of hepatic steatosis, lobular inflammation,
ballooning hepatocytes and fibrosis. Histopathological scoring of hepatic
steatosis, lobular inflammation, ballooning (degenerative) hepatocytes
and fibrosis done according to Kleiner et al. (20). Scores are listed as
16 weeks | 25 weeks (HFvHS n = 6 for fibrosis scoring at week 16 due to
technical difficulties). (DOCX 15 kb)
Abbreviations
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; BW, body weight; FFA, free fatty acids; H&E, Mayer’s
haematoxylin and eosin; HDL-C, high density lipoprotein cholesterol; HF,
high-fat; HFD, high-fat diet; HFHS, high-fat high-sucrose; HFvHS, high-fat
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